{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:21:02Z","timestamp":1791192062634,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:00:00Z","timestamp":1601078400000},"content-version":"vor","delay-in-days":1517,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM067871"],"award-info":[{"award-number":["GM067871"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1194\/jlr.m069229","type":"journal-article","created":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T01:14:08Z","timestamp":1466126048000},"page":"1552-1563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Human sterol 14\u03b1-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design"],"prefix":"10.1016","volume":"57","author":[{"given":"Tatiana Y.","family":"Hargrove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Friggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdzislaw","family":"Wawrzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneethi","family":"Sivakumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia M.","family":"Yazlovitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Hiebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Peter","family":"Guengerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Waterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina I.","family":"Lepesheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.M069229_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbagen.2006.07.018","article-title":"Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms","volume":"1770","author":"Lepesheva","year":"2007","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.M069229_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10409238309102790","article-title":"Sterol structure and membrane function","volume":"14","author":"Bloch","year":"1983","journal-title":"CRC Crit. Rev. Biochem."},{"key":"10.1194\/jlr.M069229_bib3","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1021\/cr200021m","article-title":"Biosynthesis of cholesterol and other sterols","volume":"111","author":"Nes","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1194\/jlr.M069229_bib4","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/BF02532509","article-title":"Role of sterols in membranes","volume":"9","author":"Nes","year":"1974","journal-title":"Lipids."},{"key":"10.1194\/jlr.M069229_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.mcna.2011.11.004","article-title":"Statins personalized","volume":"96","author":"Superko","year":"2012","journal-title":"Med. Clin. North Am."},{"key":"10.1194\/jlr.M069229_bib6","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/01.CIR.0000139312.10076.BA","article-title":"Update on statins: 2003","volume":"110","author":"Vaughan","year":"2004","journal-title":"Circulation."},{"key":"10.1194\/jlr.M069229_bib7","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.3390\/molecules15064129","article-title":"Conazoles","volume":"15","author":"Heeres","year":"2010","journal-title":"Molecules."},{"key":"10.1194\/jlr.M069229_bib8","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2174\/156802611796575902","article-title":"Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis","volume":"11","author":"Lepesheva","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1194\/jlr.M069229_bib9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbapap.2010.06.006","article-title":"Structural basis for conservation in the CYP51 family","volume":"1814","author":"Lepesheva","year":"2011","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.M069229_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/10409239991209246","article-title":"Lanosterol analogs: dual-action inhibitors of cholesterol biosynthesis","volume":"34","author":"Frye","year":"1999","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1194\/jlr.M069229_bib11","doi-asserted-by":"crossref","first-page":"9670","DOI":"10.1021\/bi00030a003","article-title":"Substrate-based inhibitors of lanosterol 14 alpha-methyl demethylase: I. Assessment of inhibitor structure-activity relationship and cholesterol biosynthesis inhibition properties","volume":"34","author":"Trzaskos","year":"1995","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.M069229_bib12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0022-2275(20)40001-X","article-title":"Inhibition of sterol biosynthesis in animal cells by 14 alpha-alkyl-substituted 15-oxygenated sterols","volume":"20","author":"Schroepfer","year":"1979","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M069229_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0006-2952(95)00152-P","article-title":"Azalanstat (RS-21607), a lanosterol 14\u03b1-demethylase inhibitor with cholesterol-lowering activity","volume":"50","author":"Burton","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1194\/jlr.M069229_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12035-012-8337-y","article-title":"Role of cholesterol in APP metabolism and its significance in Alzheimer's disease pathogenesis","volume":"47","author":"Maulik","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"10.1194\/jlr.M069229_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1073858410385006","article-title":"Prospects of statins in Parkinson disease","volume":"17","author":"Roy","year":"2011","journal-title":"Neuroscientist."},{"key":"10.1194\/jlr.M069229_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2014.06.007","article-title":"Statins in neurological disorders: an overview and update","volume":"88","author":"Malfitano","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1194\/jlr.M069229_bib17","first-page":"10","article-title":"The statins as anticancer agents","volume":"9","author":"Chan","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1194\/jlr.M069229_bib18","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.M069229_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00280-013-2328-1","article-title":"Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients","volume":"73","author":"Hong","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1194\/jlr.M069229_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10549-013-2473-6","article-title":"Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial","volume":"138","author":"Bjarnadottir","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1194\/jlr.M069229_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/ncponc0097","article-title":"Therapy Insight: potential of statins for cancer chemoprevention and therapy","volume":"2","author":"Katz","year":"2005","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1194\/jlr.M069229_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1517\/14740331003662620","article-title":"Statin use and cancer risk: a comprehensive review","volume":"9","author":"Boudreau","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1194\/jlr.M069229_bib23","first-page":"1","article-title":"Statins - the holy grail for cancer?","volume":"1","author":"Singh","year":"2013","journal-title":"Ann. Transl. Med."},{"key":"10.1194\/jlr.M069229_bib24","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-10-2525","article-title":"A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer","volume":"17","author":"Han","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1194\/jlr.M069229_bib25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/jnci\/djr057","article-title":"Hints that statins reduce colon cancer risk finally being put to the test","volume":"103","author":"Hede","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1194\/jlr.M069229_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jcb.10724","article-title":"Cholesterol and prostate cancer","volume":"91","author":"Freeman","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"10.1194\/jlr.M069229_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.coph.2012.07.006","article-title":"Cholesterol and prostate cancer","volume":"12","author":"Pelton","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1194\/jlr.M069229_bib28","doi-asserted-by":"crossref","first-page":"763283","DOI":"10.1155\/2012\/763283","article-title":"The role of lipid rafts in cancer cell adhesion and migration","volume":"2012","author":"Murai","year":"2012","journal-title":"Int. J. Cell Biol."},{"key":"10.1194\/jlr.M069229_bib29","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1186\/bcr3614","article-title":"A novel mechanism of regulating breast cancer cell migration via palmitoylation-dependent alterations in the lipid raft affiliation of CD44","volume":"16","author":"Babina","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1194\/jlr.M069229_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1006\/gyno.2002.6654","article-title":"Uptake of a cholesterol-rich emulsion by breast cancer","volume":"85","author":"Graziani","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1194\/jlr.M069229_bib31","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2353\/ajpath.2006.050959","article-title":"Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents","volume":"168","author":"Li","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1194\/jlr.M069229_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2010.01.022","article-title":"A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases","volume":"17","author":"Hirsch","year":"2010","journal-title":"Cancer Cell."},{"key":"10.1194\/jlr.M069229_bib33","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1158\/0008-5472.CAN-14-0130","article-title":"Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop","volume":"74","author":"Pandyra","year":"2014","journal-title":"Cancer Res."},{"key":"10.1194\/jlr.M069229_bib34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1592\/phco.30.6.541","article-title":"Statin-associated muscle-related adverse effects: a case series of 354 patients","volume":"30","author":"Cham","year":"2010","journal-title":"Pharmacotherapy."},{"key":"10.1194\/jlr.M069229_bib35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","article-title":"The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis","volume":"18","author":"Harper","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.M069229_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.phrs.2014.04.012","article-title":"Statins and skeletal muscles toxicity: From clinical trials to everyday practice","volume":"88","author":"Norata","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1194\/jlr.M069229_bib37","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.27157","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","author":"Russo","year":"2014","journal-title":"Hepatology."},{"key":"10.1194\/jlr.M069229_bib38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/2047487314550804","article-title":"Muscle- and skeletal-related side-effects of statins: tip of the iceberg?","volume":"23","author":"Auer","year":"2016","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1194\/jlr.M069229_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijcard.2011.07.048","article-title":"Managing the underestimated risk of statin-associated myopathy","volume":"159","author":"Rallidis","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1194\/jlr.M069229_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-genom-091212-153412","article-title":"Disorders of cholesterol metabolism and their unanticipated convergent mechanisms of disease","volume":"15","author":"Platt","year":"2014","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1194\/jlr.M069229_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199401133300205","article-title":"Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome","volume":"330","author":"Tint","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.M069229_bib42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/(SICI)1096-8628(20000214)90:4<339::AID-AJMG15>3.0.CO;2-5","article-title":"Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid dehydrogenase, cause CHILD syndrome","volume":"90","author":"K\u00f6nig","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"10.1194\/jlr.M069229_bib43","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/hmg\/ddg172","article-title":"Lathosterolosis: an inborn error of human and murine cholesterol synthesis due to lathosterol 5-desaturase deficiency","volume":"12","author":"Krakowiak","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1194\/jlr.M069229_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/hsz-2014-0194","article-title":"Cholesterol lowering: role in cancer prevention and treatment","volume":"396","author":"Murai","year":"2015","journal-title":"Biol. Chem."},{"key":"10.1194\/jlr.M069229_bib45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","article-title":"Mutant p53 disrupts mammary acinar morphogenesis via the mevalonate pathway","volume":"148","author":"Freed-Pastor","year":"2012","journal-title":"Cell."},{"key":"10.1194\/jlr.M069229_bib46","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/ijc.23715","article-title":"Association between plasma cholesterol and prostate cancer in the PSA era","volume":"123","author":"Platz","year":"2008","journal-title":"Int. J. Cancer."},{"key":"10.1194\/jlr.M069229_bib47","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1158\/0008-5472.CAN-05-4061","article-title":"Breast cancer growth prevention by statins","volume":"66","author":"Campbell","year":"2006","journal-title":"Cancer Res."},{"key":"10.1194\/jlr.M069229_bib48","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijpddr.2012.06.001","article-title":"CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds","volume":"2","author":"Hargrove","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1194\/jlr.M069229_bib49","doi-asserted-by":"crossref","first-page":"10789","DOI":"10.1021\/bi048967t","article-title":"CYP51 from Trypanosoma brucei is obtusifoliol-specific","volume":"43","author":"Lepesheva","year":"2004","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.M069229_bib50","doi-asserted-by":"crossref","first-page":"23916","DOI":"10.1074\/jbc.M115.677310","article-title":"Structure-functional characterization of cytochrome P450 sterol 14\u03b1-demethylase (CYP51B) from Aspergillus fumigatus and molecular basis for the development of antifungal drugs","volume":"290","author":"Hargrove","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M069229_bib51","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1074\/jbc.M109.067470","article-title":"Crystal structures of Trypanosoma brucei sterol 14 alpha-demethylase and implications for selective treatment of human infections","volume":"285","author":"Lepesheva","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M069229_bib52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1006\/abbi.1996.9859","article-title":"Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modifications of its N-terminus","volume":"339","author":"von Wachenfeldt","year":"1997","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1194\/jlr.M069229_bib53","doi-asserted-by":"crossref","first-page":"26838","DOI":"10.1074\/jbc.M111.237099","article-title":"Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14\u03b1-demethylase (CYP51) from Leishmania infantum","volume":"286","author":"Hargrove","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M069229_bib54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0026-895X(25)14748-2","article-title":"Spectral studies of drug interaction with hepatic microsomal cytochrome","volume":"3","author":"Schenkman","year":"1967","journal-title":"Mol. Pharmacol."},{"key":"10.1194\/jlr.M069229_bib55","doi-asserted-by":"crossref","first-page":"31602","DOI":"10.1074\/jbc.M113.497990","article-title":"Complexes of Trypanosoma cruzi sterol 14\u03b1-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity","volume":"288","author":"Hargrove","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M069229_bib56","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1074\/jbc.M510317200","article-title":"CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B\u2032 helix defines substrate preferences of sterol 14alpha-demethylase","volume":"281","author":"Lepesheva","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M069229_bib57","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.chembiol.2007.10.011","article-title":"Sterol 14 alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth","volume":"14","author":"Lepesheva","year":"2007","journal-title":"Chem. Biol."},{"key":"10.1194\/jlr.M069229_bib58","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1021\/jm500739f","article-title":"Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14\u03b1-demethylase: two regions of the enzyme molecule potentiate its inhibition","volume":"57","author":"Friggeri","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1194\/jlr.M069229_bib59","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1107\/S0907444903008126","article-title":"A graphical user interface to the CCP4 program suite","volume":"59","author":"Potterton","year":"2003","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1194\/jlr.M069229_bib60","doi-asserted-by":"crossref","first-page":"25582","DOI":"10.1074\/jbc.M110.133215","article-title":"Structural insights into inhibition of sterol 14 alpha-demethylase in the human pathogen Trypanosoma cruzi","volume":"285","author":"Lepesheva","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M069229_bib61","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1021\/jm801313t","article-title":"Rational modification of a candidate cancer drug for use against Chagas disease","volume":"52","author":"Kraus","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1194\/jlr.M069229_bib62","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/infdis\/jiv228","article-title":"VFV as a new effective CYP51 structure-derived drug candidate for Chagas disease and visceral leishmaniasis","volume":"212","author":"Lepesheva","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1194\/jlr.M069229_bib63","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/10428190701760011","article-title":"Statins induce lethal effects in acute myeloblastic lymphoma cells within 72 hours","volume":"49","author":"Burke","year":"2008","journal-title":"Leuk. Lymphoma."},{"key":"10.1194\/jlr.M069229_bib64","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nchembio.1337","article-title":"Metrics other than potency reveal systematic variation in responses to cancer drugs","volume":"9","author":"Fallahi-Sichani","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1194\/jlr.M069229_bib65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbagen.2015.10.015","article-title":"Ligand tunnels in T. brucei and human CYP51: Insights for parasite-specific drug design","volume":"1860","author":"Yu","year":"2016","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.M069229_bib66","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jmb.2010.01.075","article-title":"Structural basis of human CYP51 inhibition by antifungal azoles","volume":"397","author":"Strushkevich","year":"2010","journal-title":"J. Mol. Biol."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520352251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520352251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.M069229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T21:59:59Z","timestamp":1748987999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227520352251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0022227520352251"],"URL":"https:\/\/doi.org\/10.1194\/jlr.m069229","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human sterol 14\u03b1-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1194\/jlr.M069229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}]}}